PDF(Pubmed)
Abstract：
In Europe, National Immunisation Technical Advisory Groups (NITAGs) were established in most countries to promote evidence-informed decision-making in introducing new or improved vaccines or changing recommendations for existing ones. Still, the role, activities and outcomes of NITAGs have not been optimally implemented across Europe. Within the European Joint Action on Vaccination (EU-JAV), we conducted a survey to collect information on decision-making process including the main criteria for the introduction of new vaccines or changes to recommendations on their use. Between December 2021 and January 2022, 13 of the 28 European countries invited participated in an online survey. The criteria ranked as most relevant were disease burden and availability of financial resources. Only one country specified that the NITAG recommendations were binding for the government or the health authority. Vaccinations more often reported for introduction or recommendation changes were those against herpes zoster, influenza, human papillomavirus infection, pneumococcal and meningococcal disease. The planned changes will mainly address children and adolescents (2-18 years) and adults (≥ 45-65 years). Our findings show potential overlaps in the activities of NITAGs between countries; and therefore, collaboration between NITAGs may lead to optimisation of the workload and better use of resources.
摘要：
在欧洲,大多数国家都成立了国家免疫技术咨询小组（NITAG），以促进在引入新的或改进的疫苗或改变现有疫苗的建议方面的循证决策。尽管如此，角色,NITAG的活动和成果尚未在整个欧洲得到最佳实施。在欧洲疫苗接种联合行动（EU-JAV）中，我们进行了一项调查,以收集有关决策过程的信息,包括引入新疫苗的主要标准或对其使用建议的更改.在2021年12月至2022年1月期间，受邀的28个欧洲国家中有13个参加了在线调查。最相关的标准是疾病负担和财政资源的可用性。只有一个国家指出，NITAG的建议对政府或卫生当局具有约束力。更经常报告的介绍或建议更改的疫苗接种是针对带状疱疹的疫苗，流感,人乳头瘤病毒感染,肺炎球菌和脑膜炎球菌疾病。计划的变化将主要针对儿童和青少年（2-18岁）和成年人（≥45-65岁）。我们的研究结果表明，国家之间的NITAG活动可能存在重叠；因此，NITAG之间的协作可能会导致工作负载的优化和资源的更好利用。
